SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as investors scrutinize the company's path to profitability and management's effectiveness ahead of its upcoming earnings report. The community remains deeply divided, with many debating the impact of the firm's voting structure and competitive headwinds while others highlight the potential for long-term growth through its AR glasses and subscription offerings.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is driving significant debate as it navigates volatility, with bulls highlighting the stock as a profitable machine characterized by exceptional margins and strong AI ad engine momentum, while skeptics point to a recent prospectus filing for a shelf offering as a potential catalyst for dilution. Investors are closely monitoring the stock's wide price swings and its ability to maintain growth, with many in the community debating whether the current price action is a temporary shakeout or a broader re-rating of software sector valuations.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is facing severe selling pressure after providing a weak full-year earnings outlook and citing recession-level demand for appliances in North America. The community is actively debating the stock's long-term viability, with many pointing to the dividend suspension as a catalyst for forced institutional selling while contrarian traders scout for a potential bottom.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as the community highlights recent strong revenue growth and debt repayment, fueling speculation about an imminent acquisition by a larger pharmaceutical player. Investors are closely tracking near-term catalysts, including potential European regulatory approval and patent extensions, while actively debating the valuation disconnect compared to similar recent biotech sector deals.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as traders anticipate key regulatory catalysts and evaluate the company's aggressive global expansion strategy for its cell therapy technology. The community is focused on the potential for a significant short squeeze, driven by heavy short interest and high expectations for upcoming clinical data, despite ongoing frustration regarding historical FDA interactions and market volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing significant momentum and bullish sentiment following the acquisition of Mirantis, a strategic move that provides a crucial software layer for its AI cloud infrastructure and positions the company to better compete with peers like Nebius. The stock is actively trending as investors monitor potential hyperscaler contract announcements ahead of upcoming earnings, with high call volume reflecting optimism that the company is successfully executing its pivot to a full-stack AI infrastructure provider.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending due to significant attention surrounding its recent release of preclinical data on ERNA-101, which reported complete tumor clearance and long-term survival in ovarian cancer models. The community remains deeply divided, with some investors highlighting the potential of the MD Anderson collaboration and high short interest, while skeptics warn of potential dilution traps and the limitations of preclinical mouse studies.

Agilon Health, Inc. engages in the provision of healthcare services. It also provides capital, data, payor relationships, executive experience, and contract support that allow physician groups to take on the risk of total care for their patients. The company was founded by Ronald A. Williams and Veeral Desai in 2016 and is headquartered in Westerville, OH.

Agilon Health Inc

Agilon Health is trending as investors digest a series of earnings reports and leadership transitions, with community sentiment split between those viewing the current valuation as a deep-value opportunity and those concerned about ongoing management performance and potential dilution. The conversation is heavily focused on the stock's high volatility, low float, and intense speculation regarding a possible takeover or fundamental turnaround under new leadership.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors weigh strong interim Phase 3 efficacy data and Best-in-Class potential against recent price volatility, while the community remains hyper-focused on upcoming 52-week trial results. Sentiment is divided between long-term bulls highlighting scientific superiority and potential M&A activity, and skeptical traders debating the timing of institutional catalysts.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing significant volatility as investors weigh strong quarterly growth and expansion plans against concerns over long-term margins and market valuation. The community remains deeply divided, with some pointing to persistent lines and high brand loyalty as reasons to buy on dips, while others warn of potential downside risks amid broader economic pressures and high historical share sales by insiders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High  - Time to Buy?

TG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Here's Why...

<ul class="summary-bullets"><li>TG Therapeutics raised its full-year 2026 revenue outlook to about $925 million, from its earlier guidance of $875 - $900 million.</li><li>Total revenue for Q1 rose to $204.9 million, driven primarily by U.S. Briumvi sales of $194.8 million.</li><li>The company expects to report topline Phase 3 results from the Enhance trial of Briumvi around mid-2026.</li></ul>Shares of TG Therapeutics Inc. (TGTX) surged more than 8% to their highest levels in over a year, as investors embraced upbeat guidance for Briumvi, its lead candidate for multiple sclerosis.The company raised its full-year (FY) 2026 revenue outlook to about $925 million, from its earlier guidance of $875 - $900 million. It also increased its U.S. sales forecast for Briumvi to $885 - $900 million, up from the earlier $825 - $850 million range. For the second quarter (Q2), TG expects domestic Briumvi revenue of around $220 million.“With multiple near-term clinical catalysts and ongoing efforts to expand the franchise, we believe Briumvi is well-positioned to become a leading therapy in MS and a durable, long-term growth driver for TG,” said Michael S. Weiss, Chairman and CEO.<h2 class="st-heading-2">TGTX’s Q1 Print Paint Mixed Picture</h2>TG Therapeutics reported strong Q1 results, driven by growth in its lead product. Total revenue rose to $204.9 million, driven primarily by U.S. Briumvi sales of $194.8 million. This was higher than Wall Street’s $201.2 million estimate, according to Fiscal.ai data.Revenue from licensing, milestones, and royalties totalled $3.6 million, up from $1.2 million last year.The company posted net income of $19.8 million, or $0.12 per share. However, this came in sharply below consensus estimates of $0.27 per share.The company expects to report topline Phase 3 results from the Enhance trial of IV Briumvi around mid-2026. It also plans to share early Phase 1 data for azer-cel in progressive multiple sclerosis in the second half of 2026.<h2 class="st-heading-2">TGTX: Retail Turns Extremely Bullish</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/TGTX">TGTX</a> on Stocktwits turned to ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.One user said that the noise around missing earnings estimates should be ignored.<stembedurl>https://stocktwits.com/vinve/message/652414030</stembedurl>Another user expects growth to accelerate throughout 2026.<stembedurl>https://stocktwits.com/JinxyBio/message/652410967</stembedurl>The stock has jumped nearly 28% year-to-date.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tnxp-stock-rising-today-tonmya-fibromyalgia-drug-expansion/cZQz7sFReO9">TNXP Stock Climbs 7%: Retail Bets On $30M Revenue Upside From Tonmya Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss

The company increased its U.S. sales forecast for Briumvi to $885 - $900 million, up from the earlier $825 - $850 million range

Equity

TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -26.88% and +2.81%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics Inc. Q1 Profit Climbs

(RTTNews) - TG Therapeutics Inc. (TGTX.OB) released earnings for its first quarter that Increased, from last year...

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a...

Pictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTX

Pictet Asset Management Holding SA lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 9.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,461,048 shares of the biopharmaceutical company's stock after selling 148,503 sha...

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, three have given a buy reco...

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) to Release Quarterly Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-tg-therapeutics-inc-stock...

$TGTX Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.14 up 366.67% YoY
• Reported revenue of $204.92M up 69.56% YoY
• TG Therapeutics raises its full year 2026 total global revenue target to approximately $925M and its BRIUMVI U.S. net product revenue target to $885M from prior guidance of $825M.

Stocktwits

TG Therapeutics Inc

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.14 up 366.67% YoY
• Reported revenue of $204.92M up 69.56% YoY
• TG Therapeutics raises its full year 2026 total global revenue target to approximately $925M and its BRIUMVI U.S. net product revenue target to $885M from prior guidance of $825M.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Stocktwits Polls

Bullish investors are highlighting strong patient growth and an increased U.S. revenue guidance of $885M-$900M for Briumvi as key catalysts.

Retail investors are betting on a massive breakout to force shorts to cover their positions after significant volume and upward price momentum.

Persistent speculation among shareholders centers on a potential multi-billion dollar acquisition by Big Pharma, with price targets often cited above $100.

The community is eagerly anticipating upcoming readouts for Sub-Q formulation and Azer-cel trials expected within the next few weeks.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.34	--	--	N/A
Q1 '26	$0.28	$0.12	-56.44%	MISSED
Q4 '25	$0.35	$0.14	-60.28%	MISSED
Q3 '25	$0.22	$2.43	1010.24%	BEAT
Q2 '25	$0.21	$0.17	-19.49%	MISSED

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest TGTX News

TGTXTG Therapeutics Inc